Preclinical studies show that activation of the JAK-STAT3 pathway in triple negative breast cancer (TNBC) or the FGFR1/SRC/STAT3 pathway in ovarian cancer promotes tumor initiation, migration, and paclitaxel resistance [4,5,6,7]. This evidence concerns the gene STAT3 and neoplasm.